TABLE 4.
Anti-CRC effect and mechanism of TCM compounds.
Compound name | Main source | Cell lines/model | Dose | Detail | Mechanism | Ref |
---|---|---|---|---|---|---|
Berberine | Coptis chinensis | HCA 7 cells | 10–100 µM | In vitro | Result in a downregulation of 33 genes differently involved in cell cycle, differentiation and EMT | Palmieri et al. (2019) |
Evodiamine | Evodia rutaecarpa | HCT 116 cells | 5–15 µM | In vitro | Inhibit the proliferation of cells, cause accumulation of cells in S and G2/M phases, and reduce the levels of the secreted form of AMF | Zhao et al. (2015) |
Matrine | Sophora flavescens | SW 480 cells | 0.25–1.25 mM | In vitro | Trigger cell apoptosis and G0/G1 cell cycle arrest via mediation of microRNA-22 | Liu et al. (2020a) |
SW 620 cells | 0.25–1.25 mM | In vitro | ||||
Oxymatrine | Sophora flavescens | RKO cells | 0.125–8 mg/ml | In vitro | Inhibit the migration of human colorectal carcinoma via the inhibition of PAI-1 and the TGF-β1/Smad signaling pathway | Wang et al. (2017) |
Coptisine | Coptis chinensis | HCT 116 cells | 2.81–140.54 µM | In vitro | Induce apoptosis of cells by the PI3K/Akt and mitochondrial-related apoptosis pathway | Han et al. (2018) |
BALB/c mice | 50–150 mg/kg | In vivo | ||||
Lycorine | Lycoris plants | RKO cells | 10–50 µM | In vitro | Induce the activation of the caspase-dependent mitochondrial apoptotic pathway | Wu et al. (2018) |
SW 480 cells | 10–50 µM | In vitro | ||||
Piperine | Piper longum L. | HT 29 cells | 1.25 and 2.5 μg/ml | In vitro | Enhance radiosensitization by inducing the cells to apoptosis | Shaheer et al. (2020) |
Sophoridine | Sophora alopecuroide | HCT 116 cells | 40–160 µM | In vitro | Inhibits human colorectal cancer progression via targeting the MAPKAPK2 | Wang et al. (2019) |
SW 480 cells | 40–160 µM | In vitro | ||||
RKO cells | 40–160 µM | In vitro | ||||
Tetrandrine | Stephaniae tetrandrae radix | SW620 cells | 0.2–50 µM | In vitro | Suppress adhesion, migration, and invasion via the inhibition of nuclear factor-kappa B, MMP-2, and MMP-9 | Juan et al. (2018) |
Vinblastine | Catharanthus roseus | HCT 116 cells | 0.3–2.5 nM | In vitro | Inhibit tumor growth and promote angiogenesis factors | Auyeung et al. (2014) |
BALB/c mice | 0.25 mg/kg | In vivo | ||||
Homoharringtonine | Cephalotaxus fortunei | LoVo cells SW480 cells Caco-2 cells | 0.1–0.4 µM | In vitro | Suppress cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways | Shi et al. (2020) |
0.1–0.4 µM | In vitro | |||||
0.1–0.4 µM | In vitro | |||||
BALB/C mice | 0.25–1 mg/kg | In vivo | ||||
Curcumin | Curcuma longa L. | HCT 8 cells | 10 µM | In vitro | Downregulate KCNQ1OT1 expression, thus reversing cisplatin resistance in CRC cells | Zheng et al. (2021) |
Nude mice | 1 g/kg/week | In vivo | ||||
Resveratrol | Veratrum Linn. | DLD-1 cells Caco-2 cells | 40–120 µM | In vitro | Regulate several genes involved in the modulation of apoptosis such as PMAIP1, BID, and ZMAT3 | Gavrilas et al. (2019) |
40–120 µM | In vitro | |||||
Quercetin | Sophora japonica L. | Wistar rats | 50 mg/kg | In vivo | Suppress DNA damage and induce DNA repair and increase the levels and activities of enzymic, as well as the nonenzymic antioxidants | Darband et al. (2020) |
Tanshinone II A | Salvia miltiorrhiza Bge. | SW 620 cells | 0.5–10 μg/ml | In vitro | Suppress SW620 proliferation and induce apoptosis | Xue et al. (2019) |
Luteolin | Reseda odorata | HT-29 cells SW480 cells SW620 cells LoVo cells | 10–100 µM | In vitro | Upregulate miR-384 and downregulate the PTN expression level both in CRC cells and tissues | Yao et al. (2019) |
10–100 µM | In vitro | |||||
10–100 µM | In vitro | |||||
10–100 µM | In vitro | |||||
BALB/c mice | 100 mg/kg | In vivo | ||||
Genistein | Puerariae lobatae Radix | SW480 cells | 25–100 µM | In vitro | Increase the expression of TGF-β1 and lncRNA TTTY18, followed by upregulated Ki-67, serum, and SGK1 | Chen et al. (2020a) |
Baicalin | Scutellariae Radix | RKO cells | 50, 100 μg/ml | In vitro | Inhibit cell growth, migration, and invasion and induce cell apoptosis, induce cell cycle arrest in the G1 phase, and suppress both endogenous and exogenous TGFβ1-induced EMT | Yang et al. (2020) |
HCT 116 cells | 50, 100 μg/ml | In vitro | ||||
BALB/c mice | 100, 200 mg/kg | In vivo | ||||
Shikonin | Arnebiae Radix | SW 480 cells | 2.5–15 µM | In vitro | Induce mitochondria-mediated apoptosis by Bcl-2 family protein and increase the intracellular ROS | Liang et al. (2017) |
HCT 116 cells | 2.5–15 µM | In vitro | ||||
BALB/c mice | 3, 6 mg/kg | In vivo | ||||
Emodin | Rhei Radix et Rhizoma | HCT 116 cells | 15–60 μg/ml | In vitro | Block the growth and invasion of CRC cells by restraining VEGFR2 | Dai et al. (2019a) |
BALB/c mice | 20–80 mg/kg | In vivo | ||||
Cordycepin | Cordyceps sinensis | HCT 116 cells | 62.5–540 µM | In vitro | Inhibit cell growth by the endogenous Bax-dependent mitochondrial apoptosis pathway | Li et al. (2019b) |
Paeoniflorin | Paeonia lactiflora Pall. | HCT 116 cells | 2.5–40 mM | In vitro | Inhibit migration and invasion and suppress cell metastatic potential and decrease the expression of HDAC2 and vimentin, increasing E-cadherin | Zhang et al. (2018) |
SW 480 cells | 2.5–40 mM | In vitro | ||||
BALB/c mice | 1 g/kg | In vivo | ||||
Ginsenoside Rh3 | Ginseng Radix et Rhizoma | SW 1116 cells | 60–240 μg/ml | In vitro | Inhibit proliferation and increase the ratio of apoptotic cells, mRNA, and protein of caspase3 | Cong et al. (2020) |
BALB/c mice | 100, 200 mg/kg | In vivo | ||||
Andrographolide | Andrographis Herba | HCT 116 cells | 5–100 µM | In vitro | Anti-TNF-α-induced IL-8 by inhibition of NADPH oxidase/ROS/NF-κB and Src/MAPKs/AP-1 signaling pathways | Yuan et al. (2018) |
Ursolic acid | Ligustri lucidi Fructus | HCT 116 cells HCT 8 cells | 10–40 µM | In vitro | Suppress the invasive by regulating the TGF-β1/ZEB1/miR-200c signaling pathway | Zhang et al. (2019a) |
10–40 µM | In vitro | |||||
Celastrol | Tripterygium wilfordii | HCT 116 cells | 2.5–10 µM | In vitro | Inhibit proliferation, migration, and NOS activity in the cytoplasm and inhibit growth and migration | Gao et al. (2019) |
HT 29 cells | 2.5–10 µM | In vitro | ||||
Bufalin | Bufonis venenum | HCT 116 cells | 0.1–50 µM | In vitro | Reverse acquired drug resistance by inhibiting stemness in colorectal cancer cells | Sun et al. (2017) |
LoVo cells | 0.1–50 µM | In vitro | ||||
BALB/c mice | 1 mg/kg | In vivo | ||||
Norcantharidin | Mylabris phalerata Pallas. | HT 29 cells | 5, 10 μg/ml | In vitro | Cause proapoptotic and antiglycolytic effects through modulation of Fam46c expression and inhibition of ERK1/2 signaling | Zhang et al. (2020b) |
5, 10 μg/ml | In vitro | |||||
LoVo cells SW 620 cells | 5, 10 μg/ml | In vitro | ||||
Scutellarin | Erigerontis Herba | HCT 116 cells | 20–100 µM | In vitro | Reduce viability and induce apoptosis, reduce Bcl-2, and increase Bax and phosphorylation of p53 | Yang et al. (2017) |
Paeonol | Salvia miltiorrhiza Bge. | HCT 116 cells | 7.8125–500 μg/ml | In vitro | Induce G0/G1 phase arrest and cell apoptosis by inhibiting the Wnt/β-catenin signaling pathway | Liu et al. (2020b) |